NGD 981

Drug Profile

NGD 981

Latest Information Update: 07 Jan 2002

Price : $50

At a glance

  • Originator Neurogen Corporation
  • Developer Aventis Pharmaceuticals; Neurogen Corporation
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Corticotropin-releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 07 Jan 2002 Discontinued-Preclinical for Depression in USA (Unknown route)
  • 21 Dec 2001 Neurogen and Aventis are collaborating in the development of the CRF antagonist programme
  • 11 Jan 2001 The CRF antagonist programme is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top